We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Advanced Micro Devices, Inc. (AMD - Free Report) , Abbott Laboratories (ABT - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Morgan Stanley (MS - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for AMD, Abbott Labs and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Advanced Micro Devices, Inc., Abbott Laboratories and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
AMD shares have outperformed the Zacks Electronics - Semiconductors industry over the past year (+106.4% vs. +80.8%). The company is benefiting from portfolio strength and an expanding partner base. Strong demand for EPYC processors has been a growth driver.
The launch of the Ryzen 8040 series processor with Ryzen AI and Instinct MI300 Series data center AI accelerators bodes well for top-line growth. AMD continues to benefit from acquisitions, including Xilinx and Pensando, which has diversified its business. For fourth-quarter 2023, AMD expects to witness year-over-year growth in the Data Center and Client segments by double-digit percentage.
Sequentially, the Data Center segment’s revenues are expected to grow on a double-digit percentage, while Client is expected to increase. However, weakness in the Gaming and Embedded segment revenues are expected to hurt top-line growth.
Shares of Abbott Laboratories have outperformed the Zacks Medical - Products industry over the past six months (+7.6% vs. +0.6%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continues to impede overall growth in Nutrition.
Qualcomm shares have outperformed the Zacks Wireless Equipment industry over the past year (+19.7% vs. +6.6%). The company is focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge.
The company is witnessing a solid momentum in IoT and remains well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year Apple deal for 5G modems for iPhones and the launch of Snapdragon 7 Gen 3 chipsets with advanced AI features for mid-range smartphones.
However, inflationary pressures and soft recovery in China have resulting in lower-than-expected demand and elevated inventory levels. Weakness in the smartphone industry and cautious client approach are also weighing on margins. Rising geopolitical conflicts and high debt burden are other headwinds.
Other noteworthy reports we are featuring today include Morgan Stanley and Intuitive Surgical, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical
For Immediate Release
Chicago, IL – January 16, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Advanced Micro Devices, Inc. (AMD - Free Report) , Abbott Laboratories (ABT - Free Report) , Qualcomm Inc. (QCOM - Free Report) , Morgan Stanley (MS - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for AMD, Abbott Labs and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Advanced Micro Devices, Inc., Abbott Laboratories and Qualcomm Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
AMD shares have outperformed the Zacks Electronics - Semiconductors industry over the past year (+106.4% vs. +80.8%). The company is benefiting from portfolio strength and an expanding partner base. Strong demand for EPYC processors has been a growth driver.
The launch of the Ryzen 8040 series processor with Ryzen AI and Instinct MI300 Series data center AI accelerators bodes well for top-line growth. AMD continues to benefit from acquisitions, including Xilinx and Pensando, which has diversified its business. For fourth-quarter 2023, AMD expects to witness year-over-year growth in the Data Center and Client segments by double-digit percentage.
Sequentially, the Data Center segment’s revenues are expected to grow on a double-digit percentage, while Client is expected to increase. However, weakness in the Gaming and Embedded segment revenues are expected to hurt top-line growth.
(You can read the full research report on AMD here >>>)
Shares of Abbott Laboratories have outperformed the Zacks Medical - Products industry over the past six months (+7.6% vs. +0.6%). The company is strategically expanding its global presence to address the unmet demand for advanced medical technologies. Within the EPD business, which is solely based in emerging markets.
Within Core Diagnostics, Abbott is gaining market share following the end of the public health emergency, particularly in the United States and Europe region. Within Diabetes Care, Abbott is scaling up the production of Libre and gaining reimbursement approval in several countries. Innovations and market expansion efforts are helping it offset the impact of inflation and supply disruptions.
However, a steep year-over-year decline in COVID testing-related sales hurt growth. Further, the decision to exit the pediatric nutrition business in China continues to impede overall growth in Nutrition.
(You can read the full research report on Abbott Laboratories here >>>)
Qualcomm shares have outperformed the Zacks Wireless Equipment industry over the past year (+19.7% vs. +6.6%). The company is focusing on the seamless transition from a wireless communications firm for the mobile industry to a connected processor firm for the intelligent edge.
The company is witnessing a solid momentum in IoT and remains well poised to benefit from solid 5G traction, greater visibility and a diversified revenue stream. Strength in the snapdragon portfolio is an additional tailwind as exemplified by the multi-year Apple deal for 5G modems for iPhones and the launch of Snapdragon 7 Gen 3 chipsets with advanced AI features for mid-range smartphones.
However, inflationary pressures and soft recovery in China have resulting in lower-than-expected demand and elevated inventory levels. Weakness in the smartphone industry and cautious client approach are also weighing on margins. Rising geopolitical conflicts and high debt burden are other headwinds.
(You can read the full research report on Qualcomm here >>>)
Other noteworthy reports we are featuring today include Morgan Stanley and Intuitive Surgical, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.